Meeting
2013 ASCO Annual Meeting
Phase I/Ib study of the PARP inhibitor olaparib (O) with carboplatin (C) in BRCA1/2 mutation carriers with breast or ovarian cancer (Br/OvCa) (NCT00647062).
Authors
Jung-min Lee
Molecular Signaling Section, Medical Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD
Jung-min Lee , Christina M. Annunziata , John L. Hays , Anne M. Noonan , Lori M. Minasian , JoAnne Zujewski , Minshu Yu , Jiuping Jay Ji , Tristan Sissung , Nicole D. Houston , Elise C. Kohn
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Developmental Therapeutics - Clinical Pharmacology and Experimental Therapeutics
Track
Developmental Therapeutics
Sub Track
DNA Repair and Apoptosis
Clinical Trial Registration Number
NCT00647062
Citation
J Clin Oncol 31, 2013 (suppl; abstr 2514)
DOI
10.1200/jco.2013.31.15_suppl.2514
Abstract #
2514
Poster Bd #
2
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
Analysis of candidate homologous repair deficiency genes in a clinical trial of olaparib in patients (pts) with platinum-sensitive, relapsed serous ovarian cancer (PSR SOC).
First Author: Brian Dougherty
Poster
2011 ASCO Annual Meeting
Phase I study of the PARP inhibitor olaparib (O) in combination with carboplatin (C) in BRCA1/2 mutation carriers with breast (Br) or ovarian (Ov) cancer (Ca).
First Author: J. Lee
Poster
2021 ASCO Annual Meeting
Phase 1b/2 SEASTAR trial: Safety, pharmacokinetics, and preliminary efficacy of the poly(ADP)-ribose polymerase (PARP) inhibitor rucaparib and angiogenesis inhibitor lucitanib in patients with advanced solid tumors.
First Author: Ecaterina Elena Dumbrava
Poster
2018 ASCO Annual Meeting
Locus-specific loss of heterozygosity (LOH) in BRCA1/2 mutated (mBRCA) ovarian tumors from the SOLO2 (NCT01874353) and Study 19 (NCT00753545) clinical trials.
First Author: Kirsten Timms